Holen Sie sich die Stockscreener-App
121.00
13.47%
14.36
Handel nachbörslich:
122.00
1.00
+0.83%
Schlusskurs vom Vortag:
$106.64
Offen:
$103.55
24-Stunden-Volumen:
1.79M
Relative Volume:
2.11
Marktkapitalisierung:
$6.95B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-40.88
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
+10.98%
1M Leistung:
+0.63%
6M Leistung:
+35.17%
1J Leistung:
-20.89%
1-Tages-Spanne:
$103.55
$121.69
1-Wochen-Bereich:
$103.55
$121.69
52-Wochen-Spanne:
$73.16
$161.78
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
121.00 | 6.12B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Needham raises Glaukos stock price target on iDose, Epioxa growth By Investing.com - Investing.com Nigeria
Why Analysts See Glaukos (GKOS) Story Shifting As iDose Repeat Dosing Takes Center Stage - Yahoo Finance
Glaukos Corp. Earnings Call Signals High-Growth Phase - TipRanks
Glaukos (NYSE:GKOS) Jumps After Qtrly Revenue Beat - Kalkine Media
Glaukos (NYSE:GKOS) Trading 8.4% HigherWhat's Next? - MarketBeat
Stifel reiterates Glaukos stock rating on product momentum - Investing.com Nigeria
Glaukos Stock Shoots Up After iDose TR Re-administration Approval - StocksToTrade
Glaukos (GKOS): Wells Fargo Raises Price Target to $135 | GKOS S - GuruFocus
These Analysts Boost Their Forecasts On Glaukos Following Q4 Results - Benzinga
Needham raises Glaukos stock price target on iDose, Epioxa growth - Investing.com
BTIG Research Reaffirms Buy Rating for Glaukos (NYSE:GKOS) - MarketBeat
Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript - Insider Monkey
BTIG Reiterates Buy Rating for Glaukos (GKOS) with Unchanged Pri - GuruFocus
Glaukos (GKOS) Surpasses Revenue Expectations with Strong Q4 Per - GuruFocus
Glaukos Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Glaukos Corp (GKOS) Q4 2025 Earnings Call Highlights: Record Sal - GuruFocus
Glaukos Q4 Earnings Call Highlights - MarketBeat
Glaukos (GKOS) Q4 2025 Earnings Call Transcript - The Globe and Mail
Glaukos (GKOS) Anticipates $600M-$620M Revenue for FY26 - GuruFocus
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance UK
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Glaukos: Q4 Earnings Snapshot - kens5.com
Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook - TipRanks
Glaukos (NYSE:GKOS) Issues Earnings Results - MarketBeat
Glaukos Q4 Non-GAAP Loss Narrows, Sales Rise - marketscreener.com
Glaukos Q4 Earnings Summary & Key Takeaways - Benzinga
Earnings Flash (GKOS) Glaukos Corporation Reports Q4 Revenue $143.1M, vs. FactSet Est of $136.4M - marketscreener.com
Insider Buy: Why is Glaukos Corporation stock going up2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Glaukos earnings on deck as iDose, Epioxa launches converge - Investing.com UK
Glaukos earnings on deck as iDose, Epioxa launches converge By Investing.com - Investing.com India
Glaukos: Fourth Quarter Financial Highlights - Bitget
Wellington Management Group LLP Significantly Reduces Stake in G - GuruFocus
Glaukos Corporation (GKOS) Investor Outlook: Analyzing the 21% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Can Glaukos Corporation stock hit record highs againJuly 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
Aug Movers: Is Glaukos Corporation a defensive stock2025 Retail Activity & Safe Entry Momentum Tips - baoquankhu1.vn
Glaukos (GKOS) Q4 Earnings Preview: Revenue Growth Expected - GuruFocus
Public Sector Pension Investment Board Purchases 28,866 Shares of Glaukos Corporation $GKOS - MarketBeat
Should I buy Glaukos Corporation (6GJ) stock before earnings seasonJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
Is Glaukos Corporation stock positioned for long term growthJuly 2025 Drop Watch & Technical Entry and Exit Alerts - mfd.ru
(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Does Glaukos Corporation meet Warren Buffett’s criteriaWeekly Trend Recap & Capital Efficient Trading Techniques - mfd.ru
Why Glaukos Corporation stock remains undervaluedQuarterly Profit Review & Verified Chart Pattern Signals - mfd.ru
Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Stifel reiterates Buy rating on Glaukos stock with $160 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Glaukos stock with $160 price target - Investing.com Australia
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
What is Glaukos Corporation’s market position2025 Major Catalysts & Weekly Momentum Picks - mfd.ru
Glaukos (GKOS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Glaukos Corporation $GKOS Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):